A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Researcher Information

Olga G. Goloubeva, Ph.D., M.Sc.
Associate Professor


Department:
Department of Epidemiology and Public Health
Division of Biostatistics and Bioinformatics


UMGCC Research Program:
Hormone Responsive Cancers Program

Education/Training:
College Degree: B.Sc., M.Sc., National University of Science and Technology, Moscow, Russia
M.Sc., Dalhousie University, Halifax, NS, Canada
Post Doctoral Degree: Ph.D., State Technical University, Moscow, Russia (accredited by the University of Toronto, Toronto, Canada)

Contact Information:

Mailing Address: Division of Biostatistics & Bioinformatics
University of Maryland Greenebaum Cancer Center
Howard Hall, 111
660 W Redwood Street
Baltimore, Maryland 21201
Email: ogoloubeva@som.umaryland.edu
Phone: 410-706-8502
Fax: 410-706-8548

Research Interests:
Statistical design and analysis of laboratory, clinical and epidemiological studies in all types of cancer as well as other diseases.
Statistical expertise lies in the design and analysis of preclinical studies and clinical trials, evaluation of diagnostic tests, biomarkers and their combination, prognostic models of cancer, longitudinal and hierarchical data modeling.


Publications:
Gauri Sabnis, Olga Goloubeva, Saranya Chumsri, Nguyen Nguyen, Saraswati Sukumar, and Angela Brodie. Functional reactivation of the estrogen receptor-and aromatase by the HDAC inhibitor, entonostat, increases sensitivity of ER-negative tumors to letrozole. Cancer Res, 2011. Mar 1: 71(5): 1893-903. (Data analysis, manuscript writing).

Marshal Posner, Jochen H Lorch, Olga Goloubeva, Ming Tan, Nicholas Sarlis, Robert Haddard, Kevin Cullen. Survival and Human Papillomavirus in Oropharynx Cancer in TAX 324: A Subset Analysis from an International Phase III Trial. Annals of Oncology. Accepted. January 2011. (Data analysis, manuscript writing).

Lorch J, Goloubeva O, Haddard R., Cullen K., Sarlis N., Tan M., Posner M: Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncology. 2011 Feb: 12(2):153-9. (Data analysis, manuscript writing).

Lorch J, Goloubeva O, Posner M: How does TPF improve survival over PF? Authorsâ?T reply. Lancet Oncology, 2011 May; 12(5): 421-2.

Suntharalingam M, Kwok Y, Goloubeva O, Parekh A, Taylor R, Wolf J, Zimrin A, Strome S, Ord R, Cullen KJ. Phase II Study Evaluating the Addition of Cetuximab to the Concurrent Delivery of Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy for Patients With Locally Advanced Squamous Cell Carcinomas of the Head and Neck. Int J Radiat Oncol Biol Phys. 2011 May 19 (Data analysis, manuscript writing).

Neuner G, Mohiuddin MM, Walde NV, Goloubeva O, Yu CX, Regine WF. High-dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment outcomes with cerrobend vs. MLC SFGRT. Int J Radiat Oncol Biol Phys. 2011 April 29 (Data analysis, manuscript writing).

Kundu N, Campbell P, Hampton B, Lin CY, Ma X, Ambulos N, Zhao XF, Goloubeva O, Holt D, Fulton AM. Antimetastatic activity isolated from Colocasia esculenta Anticancer Drugs. 2011 Sep 22.

Tkaczuk KH, Tait NS, Ioffe O, Tan M, Goloubeva OG, Lesko SA, Deamond SF, Zhou D, Lum ZP, Sutula MJ, Van Echo D, Ts'o PO. Computer assisted quantitative immunofluorescence of tumor tissue marker expression and clinical outcome to chemotherapy in advanced breast cancer patients. Discov Med. 2011 Jul;12(62):33-40.

Ma X, Kundu N, Collin PD, Goloubeva O, Fulton AM. Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2.Breast Cancer Res Treat. 2011 Jul 15.

Usama Mahmood; Matthew Koshy; Olga Goloubeva; Mohan Suntharalingam. Adjuvant Radiation Therapy for High-Grade and/or Locally Advanced Major Salivary Gland Tumors. Arch Otolaryngol Head Neck Surg. 2011;137(10):1025-1030.